Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.94), in-line with the analyst estimate of ($0.94). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $510 thousand.

GUIDANCE:

Revance reiterates its financial guidance provided in January 2018. Revance expects cash burn for 2018 to be in the range of $117 to $137 million. Revance expects 2018 GAAP operating expense to be in the range of $128 to $154 million, which when excluding depreciation of $1 to $3 million and estimated stock-based compensation of $17 to $21 million, results in projected 2018 non-GAAPoperating expense of $110 to $130 million, driven by increased research and development expenditure and launch preparation activities

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.